Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Daniel V.T. Catenacci, Yung‐Jue Bang, Yoon‐Koo Kang et al.|The Lancet Oncology|2020

Cited by 190